Optimising Hepatitis C Treatment for People Who Inject Drugs: Developing a GP-led Patient Pathway

  • Whiteley, David (PI)
  • Elliott, Lawrence (CoI)
  • Flowers, Paul, University of Strathclyde (CoI)
  • Davidson, Katherine, NHS Lothian (CoI)
  • Jarvis, Helen, Newcastle University (CoI)
  • Quinn, Michael, NHS Lothian (CoI)
  • Hamilton, Emma, Scottish Drugs Forum (CoI)

Project Details

Description

The hepatitis C virus (HCV) is a serious infection that attacks the liver, and is a leading cause of
mortality and morbidity worldwide. In Scotland, approximately 37,000 people are infected, with over
85% of these infections in people who inject, or have injected drugs (PWID). Treatment for HCV is
simple, tolerable and effective. However, treatment uptake is estimated at only 5-6%. This means
that tens of thousands of people are suffering unnecessarily. The reasons for such low uptake relate
to multiple interruptions in the journey through care, not least the difficulty of linking those diagnosed
with HCV into treatment. One strategy to improve this is the movement of HCV treatment away from
traditional specialist centres, and into primary care. This has been achieved successfully elsewhere
in the world in other health care systems.
Short titleDeveloping a GP-led hepatitis C treatment pathway
StatusFinished
Effective start/end date1/07/1930/09/21

Funding

  • Chief Scientist Office: £23,959.00

UN Sustainable Development Goals

In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This project contributes towards the following SDG(s):

  • SDG 3 - Good Health and Well-being

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.